News

The company has received funds worth £450,000 from Finance Wales, Acceleris, Welsh Government and Denbighshire County Council, which would support its entry into the next phase of development,

The Phase 1 study involved 32 patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), and will determine the maximum tolerated dose (MTD), dose limiting

ATX-101, an injectable drug being studied for the reduction of localized fat is a proprietary formulation of deoxycholate, an endogenous compound that is present in the body to

The collaboration signed in December 2009, has been extended to an additional year through December 2012. Initially Bristol-Myers Squibb paid NeurOp a licensing fee of $1.5m and agreed

The two randomized double-blind placebo-controlled trials Phase III efficacy trials- BLOOM-1 and BLOOM-2 enrolled 597 and 575 surgically menopausal women, respectively, for six-months of therapy. In the BLOOM-1

According to the company, the new solution provides visibility into all the complexities of patient financial clearance in a single, easy-to-use application, besides increasing efficiency and reducing errors

The Siberian Ginseng (Acanthopanax) Polysaccharide is extracted from the stem of Siberian Ginseng by proprietary extraction technology separating and extracting effective parts of the Siberian Ginseng. The powder

The 18-month randomized, parallel group, double-blind, placebo-controlled trial conducted in 512 ALS patients evaluated the efficacy and safety of olesoxime against placebo in patients treated with riluzole. Olesoxime

Kun Tuo will lay emphasis on the development of customized solutions to help local and global biopharma companies achieve registration of new medicines in China. In addition the